DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT01226966

EVIDENCE

Completed

Observational Study on Efficacy and Safety of Liraglutide in Subjects With Type 2 Diabetes

Conditions for Prescribing Liraglutide in Medical Practice and Assessment of Maintenance Level, Tolerability, and Efficacy of Victoza® (Liraglutide) in Subjects With Type 2 Diabetes

Lead sponsor

Novo Nordisk A/S

Asset

Liraglutide

Subcutaneous · GLP-1 agonist

Listed sites

1

Recruiting sites

—

Enrollment

3,152

actual

Study population

Type 2 diabetes

Key I/E criterion

—

Primary endpoint

•HbA1c <7.0% achievement

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT01226966
Org study IDNN2211-3815
Secondary IDU1111-1116-2722WHO

Timeline

Milestones

Study first posted2010-10-22estimated
Last update posted2017-02-13actual
Study start2010-09 (month precision)
Primary completion2013-11actual (month precision)
Study completion2013-11actual (month precision)

Assets

Investigational agents

Liraglutide

Study populations

Who this study enrolls

Type 2 diabetes

Eligibility

Who can enroll

Minimum age18 Years
SexAll
Healthy volunteersNot accepted
Sampling methodNon probability sample

Study population text

Patients starting or having recently started liraglutide treatment for less than one week, and satisfying the study inclusion and exclusion criteria.

Inclusion criteria

•Patients diagnosed with type 2 diabetes
•Patients having recently started (for less than one week) or starting liraglutide (Victoza®) treatment

Exclusion criteria

•Hypersensitivity (allergy) to liraglutide or to any of the excipients
•Patient is participating in a clinical trial at the inclusion
•Type 1 diabetes

Endpoints (16)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Glycemic / diabetes
11
Weight & body composition
5

Weight & body composition

5 endpoints
Secondary/protocol endpoint

Change in Body Weight at Month 3

Time frame:Month 0, Month 3

Body weight, absolute change (kg)

change from baseline, improvement

Secondary/protocol endpoint

Change in Body Weight at Month 6

Time frame:Month 0, Month 6

Body weight, absolute change (kg)

change from baseline, improvement

Secondary/protocol endpoint

Change in Body Weight at Month 12

Time frame:Month 0, Month 12

Body weight, absolute change (kg)

change from baseline, improvement

Secondary/protocol endpoint

Change in Body Weight at Month 18

Time frame:Month 0, Month 18

Body weight, absolute change (kg)

change from baseline, improvement

Secondary/protocol endpoint

Change in Body Weight at Month 24

Time frame:Month 0, Month 24

Body weight, absolute change (kg)

change from baseline, improvement

Glycemic / diabetes

11 endpoints
Primary/protocol endpoint

Percentage of patients still in liraglutide treatment and having a HbA1c (glycosylated haemoglobin) value below 7.0%

Time frame:Month 24

HbA1c <7.0% achievement

threshold achievement, improvement

LOINC 4548-4

Secondary/protocol endpoint

Change in HbA1c at month 3

Time frame:Month 0, Month 3

HbA1c, change

change from baseline, improvement

LOINC 4548-4

Secondary/protocol endpoint

Change in HbA1c at month 6

Time frame:Month 0, Month 6

HbA1c, change

change from baseline, improvement

LOINC 4548-4

Secondary/protocol endpoint

Change in HbA1c at month 12

Time frame:Month 0, Month 12

HbA1c, change

change from baseline, improvement

LOINC 4548-4

Secondary/protocol endpoint

Change in HbA1c at month 18

Time frame:Month 0, Month 18

HbA1c, change

change from baseline, improvement

LOINC 4548-4

Secondary/protocol endpoint

Change in HbA1c at month 24

Time frame:Month 0, Month 24

HbA1c, change

change from baseline, improvement

LOINC 4548-4

Secondary/protocol endpoint

Change in fasting plasma glucose (FPG) at month 3

Time frame:Month 0, Month 3

Fasting glucose, change

change from baseline, improvement

LOINC 1558-6

Secondary/protocol endpoint

Change in fasting plasma glucose (FPG) at month 6

Time frame:Month 0, Month 6

Fasting glucose, change

change from baseline, improvement

LOINC 1558-6

Secondary/protocol endpoint

Change in fasting plasma glucose (FPG) at month 12

Time frame:Month 0, Month 12

Fasting glucose, change

change from baseline, improvement

LOINC 1558-6

Secondary/protocol endpoint

Change in fasting plasma glucose (FPG) at month 18

Time frame:Month 0, Month 18

Fasting glucose, change

change from baseline, improvement

LOINC 1558-6

Secondary/protocol endpoint

Change in fasting plasma glucose (FPG) at month 24

Time frame:Month 0, Month 24

Fasting glucose, change

change from baseline, improvement

LOINC 1558-6

Publications (2)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.